Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733915 | 0.85 | ADORA2A (0.74) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| Pbf-509 SCHEMBL21980568 | 0.78 | ADORA2A (0.94) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| Pbf-509 SCHEMBL30798032 | 0.78 | ADORA2A (0.94) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| Pbf-509 SCHEMBL30797853 | 0.78 | ADORA2A (0.94) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| Pbf-509 SCHEMBL2546228 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL2548427 | 0.78 | ADORA2A (0.71) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| Pbf-509 SCHEMBL29421140 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL2545691 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| Pbf-509 SCHEMBL20576730 | 0.76 | ADORA2A (0.97) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL29440767 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552909-B1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2015-03-11 | — | — | EP | claimed |
| CN-102892761-B | 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists | PALOBIOFARMA SL | 2015-02-04 | — | — | CN | claimed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | claimed |
| EP-2552909-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2013-02-06 | — | — | EP | claimed |
| WO-2011121418-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2011-10-06 | — | — | WO | claimed |
| CN-114129568-A | 5-bromo-2, 6-di- (1H-pyrazol-1-yl) pyrimidin-4-amines for the treatment of cancer | 诺华股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-108348521-B | 5-bromo-2, 6-di- (1H-pyrazol-1-yl) pyrimidin-4-amines for the treatment of cancer | 诺华股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-3334431-B9 | 5-BROMO-2,6-DI-(1H-PYRAZOL-L-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-10561653-B2 | 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | NOVARTIS AG (CH) | 2020-02-18 | — | — | US | disclosed |
| EP-3334431-B1 | 5-BROMO-2,6-DI-(1H-PYRAZOL-L-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | disclosed |
| EP-3334431-A1 | 5-BROMO-2,6-DI-(LH-PYRAZOL-L-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER | Novartis AG (CH) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017025918-A1 | 5-BROMO-2,6-DI-(LH-PYRAZOL-L-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| US-8796284-B2 | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2014-08-05 | — | — | US | disclosed |
| US-8796284-B2 | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2014-08-05 | — | — | US | disclosed |
| US-8796284-B2 | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2014-08-05 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
| EP-2552909-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011121418-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA3 3/4885 |
| US-10561653-B2 | 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | BRD4, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADORA2A 516/4885ADORA1 1171/4885ADORA3 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.